Racial differences in primary cytogenetic abnormalities in multiple myeloma: A multi-center study

Blood Cancer Journal

Volumn 5, Issue 1, 2015, Pages e271-

  Greenberg, A J ^a   Philip, S ^b   Paner, A ^c   Velinova, S ^d   Badros, A ^b   Catchatourian, R ^d   Ketterling, R ^a   Kyle, R A ^a   Kumar, S ^a   Vachon, C M ^a   Rajkumar, S V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONGENITAL MALFORMATION; CYTODIAGNOSIS; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MULTICENTER STUDY; MULTIPLE MYELOMA; PREVALENCE; PROTEIN TARGETING; RACE DIFFERENCE; TRISOMY; VERY ELDERLY; BLACK PERSON; CAUCASIAN; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME ABERRATION; CLINICAL TRIAL; GENE TRANSLOCATION; GENETICS; KARYOTYPING; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 17; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 84927748520     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.91     Document Type: Article

References (19)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncol 2014; 15: e538-e548.
2. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28: 398-403.
3. Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 998-1009.
4. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R et al. Racial disparities in the prevalence of monoclonal gammopathies: a populationbased study of 12 482 persons from the national health and nutritional examination survey. Leukemia 2014; 28: 1537-1542.
5. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904-906.
6. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012; 26: 609-614.
7. Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999; 85: 2385-2390.
8. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.[erratum appears in Am J Med 1998;105(4):362]. Am J Med 1998; 104: 439-444.
9. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82: 1468-1473.
10. Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance (MGUS) among African-American and Caucasian women. Blood 2010; 116: 1056-1059.
11. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: a populationbased study. Blood 2010; 116: 5501-5506.
12. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
13. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
14. Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood 2013; 121: 3147-3152.
15. Fonseca R. Many and multiple myeloma(s). Leukemia 2003; 17: 1943-1944.
16. Pandey S, Rajkumar SV, Kapoor P, Ketterling RP, Lacy MQ, Gertz MA et al. Impact of FISH abnormalities on response to lenalidomide in patients with multiple myeloma. Blood 2013; 122: 3210.
17. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
18. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011; 1: e41.
19. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013; 3: e143.